AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$GH

Guardant Health (GH) Q3 2026 Earnings Call Transcript

Guardant Health (GH) reported Q3 2026 revenue growth of 36% to $361M. Oncology revenue rose 25% to $231M, with test volumes up 58%. The company received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH, and submitted a PMA application for Guardant360 Tissue. They also announced the launch of 11 new Smart Apps for Guardant360 Liquid.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 7:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Guardant Health (GH) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GHBullishHigh
01

Why it matters

The FDA clearance is a fresh, material development that could drive share price appreciation and expand market share in liquid biopsy diagnostics.

02

Market read

New regulatory approval combined with strong earnings may create a short‑term buying opportunity.

03

What to watch

Reimbursement timelines and payer acceptance could limit near‑term revenue impact.

Relevance 8/10Novelty 9/10Timing: immediate

Background

Guardant Health presented its Q3 2026 earnings call, highlighting revenue growth and a new FDA approval for its Guardant360 CDx test.

Company-level read

Ticker impact

$GHBullishHigh confidence
Context

Q3 2026 earnings released with 36% revenue growth to $361M and FDA approval of Guardant360 CDx companion diagnostic.

Expected impact

likely upside as investors price in the regulatory win and higher test volumes.

Evidence & confidence

Regulatory clearance is a material catalyst for Guardant Health, historically driving share price appreciation.

Market effects

Sector

Strengthens the liquid biopsy and precision oncology sector, potentially boosting peers.

Regional

U.S. biotech market may see modest gains from the approval.

Global

Adds to global trend of expanding companion diagnostics for targeted therapies.

Counterpoint

What could challenge this read

If adoption is slower than expected, the approval may be already priced in.

Key entities

  • company
    Guardant Health

    U.S.-listed precision oncology diagnostics firm.

  • partner
    AstraZeneca

    Pharma partner for the Guardant360 CDx companion diagnostic.

Read at source← All news

Also covered by

1 outlet

Related articles

$GHHighAI 8/10

Guardant Health stock reiterated at Buy by BTIG after Q3 beat

BTIG reiterated a Buy rating on Guardant Health (GH) with a $210 price target after Q3 results. GH beat revenue estimates by 3% and raised 2026 guidance. Shares fell 5% in after-hours trading. The company reported 36% revenue growth and adjusted earnings of -$0.29 per share, better than expected. BTIG noted strong growth in oncology and screening businesses, designating GH as a Top Pick.

investing.com
$GHHighAI 8/10

Why is Guardant Health stock sliding today?

Guardant Health (GH) shares fell 5.5% premarket after Q3 2026 results showed revenue of $361M (up 36% YoY) and EPS of -$0.29 (beating estimates). The stock declined due to increased full-year free cash flow burn guidance of $205M-$220M, up from $195M-$205M. Revenue guidance was raised to $1.36B-$1.37B, in line with consensus.

investing.com
$GHMed

Guardant Health Inc (GH) (Q3 2026) Earnings Call Highlights: Revenue Surges 36%

Guardant Health (GH) reported a 36% revenue surge in Q3 2026. Free cash flow burn guidance increased to $205-$220M due to CMS delays. Non-GAAP operating expenses rose 26% to $287M. Shield ASP may decrease short-term due to patient mix shifts. Reveal Ultra launch is planned for year-end, but Medicare coverage is pending. The company faces reimbursement challenges for quarterly ESR1 testing.

finance.yahoo.com
$GHHighAI 8/10

What Guardant Health (GH) Said on Its Q3 Earnings Call

Guardant Health (GH) reported Q3 earnings, with oncology revenue up 25% to $231M and test volume rising 58%. Shield's average selling price was above $800, with expectations of short-term decline. The company maintained its 2026 outlook for 30% oncology revenue growth and now expects over 50% volume growth. Non-GAAP gross margin improved to 67%, and adjusted EBITDA loss narrowed to $37M. Guardant also highlighted FDA approvals and plans for new product launches.

finance.yahoo.com